Viridos is a company that develops algal biofuel technology aimed at addressing climate change and providing decarbonization solutions for various industries.

Viridos

CRISPR Biotech Engineering is an early-stage genome editing company that is committed to using innovative CRISPR-Cas9 technology to improve human lives.

CRISPR Biotech Engineering

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Austin Che

Tom Knight

Jason Kelly

Barry Canton

Reshma Shetty

Ginkgo Bioworks Holdings, Inc.

Viridos is a privately held biotechnology company harnessing the power of photosynthesis to create transformative solutions to mitigate climate change. Our unparalleled understanding of algal genetics and ability to translate innovation from lab to field underpins our initial deployment: a scalable platform to produce low-carbon intensity biofuels for aviation, commercial trucking, and maritime shipping. Building on a legacy of genomic firsts, our team of scientists and engineers are shaping new pathways toward a sustainable bioeconomy. To learn more, visit us at Viridos.com. 

Metric
Company Name	Viridos	CRISPR Biotech Engineering	Ginkgo Bioworks Holdings, Inc.
Symbol			DNA
MSH ID	COM:VIRIDOS	COM:CRISPR-BTE	COM:GINKGOBIOWORKS
Market	PRIVATE	PRIVATE	STOCKS
Sector	Energy	Healthcare & Health Services	Healthcare
Industry	Renewable Energy	Biotechnology	Biotechnology
Country	US	GB	US
Stage			Grant
Employee Count	99		1.22K
Website	viridos.com	crispr-bte.com	ginkgobioworks.com
LinkedIn	viridosinc		ginkgo-bioworks
Founders

Metric
Market Cap			725.64M
Enterprise Value
Monthly Web Traffic			20.69K
Web Traffic Growth			-0.17
Valuation
Raised Capital

Metric
Revenue			251.46M
Revenue (LTM)
Revenue (NTM)
Gross Profit			142.64M
EBITDA			-600.68M
Operating Income			-672.23M
Net Income			-892.87M
EPS			-0.46
Diluted EPS			-0.46
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.75
Operating Profit Margin			-3.34
EBITDA Margin			-2.39
Net Profit Margin			-3.55
Return on Equity			-0.65
Return on Assets			-0.54
Return on Capital Employed			-0.51

COM:VIRIDOS

Viridos

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			-2.78
P/B Ratio			1.90
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			93.70
EV Multiple			-1.34

Metric
Days Sales Outstanding			73.17
Days Payables Outstanding			50.57
Days Inventory Outstanding			0.27
Operating Cycle			46.33
Cash Conversion Cycle			-7.39
Asset Turnover			0.15

Metric
Operating Cash Flow			-295.50M
Free Cash Flow			-336.30M
Cash Flow to Debt			-0.63
Operating Cash Flow/Sales			-1.14
Free Cash Flow Yield			-0.16

Metric
Cash & Equivalents			948.86M
Accounts Receivable			50.07M
Inventory			46K
Goodwill			49.24M
Debt to Capitalization			0.35
Debt to Assets			0.20
Current Ratio			6.78
Quick Ratio			5.98

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.94
R&D to Revenue			2.05
SG&A to Revenue			1.32